{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"XTL Biopharmaceuticals Ltd."},"Symbol":{"label":"Symbol","value":"XTLB"},"Address":{"label":"Address","value":"5 BADNER STREET P.O.BOX 8241, RAMAT GAN, 4365603, Israel"},"Phone":{"label":"Phone","value":"+972 36116600"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"Middle East"},"CompanyDescription":{"label":"Company Description","value":"XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia."},"CompanyUrl":{"label":"Company Url","value":"https://www.xtlbio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Daphna Paran","title":"Medical Director"},{"name":"Shlomo Spokone Shalev","title":"Chief Executive Officer & Executive Director"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}